Rapport Therapeutics, Inc. Common Stock (RAPP) Stock Price

RAPPStock
$51.17+233.99%52W
Market Cap$2.46B
P/E
PEG Ratio
Div yield
Beta2.47

RAPP Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)57.69%
Price vs S&P 500 (4W)14.51%
VGM Score82.07

RAPP Earnings Surprise History

Q2 25-0.75est. -0.77
Q3 25-0.71est. -0.73
Q4 25-0.72est. -0.67
Q1 26-0.42est. -0.71
Q2 26-1.19est. -0.99

RAPP Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.29
4.29
4.33
4.37

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
RAPPRapport Therapeutics, Inc. Common Stock
A$51.17
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Rapport Therapeutics, Inc. Common Stock

Rapport Therapeutics is a clinical-stage biotechnology company developing small-molecule precision medicines for neurological and psychiatric disorders. Its lead program, RAP-219, is in clinical development for focal onset seizures, generalized tonic-clonic seizures, and bipolar mania. The company also maintains two discovery-stage nicotinic acetylcholine receptor programs targeting chronic pain and hearing disorders.